AVANIR To Present at the Rodman & Renshaw 10th Annual Healthcare Conference
ALISO VIEJO, Calif., November 4, 2008 - AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced that Keith Katkin, President and Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11 at 4:55 p.m. Eastern time (1:55 p.m. Pacific time). This conference will be held at the New York Palace Hotel in New York. The Rodman and Renshaw Healthcare Conference provides the opportunity for participating companies to present to institutional investors, venture capitalists, sophisticated private investors, and business development and partnering executives. Since 2003, the Rodman & Renshaw Healthcare Conference has been a premier event on the life sciences calendar. For more information visit http://www.rodmanandrenshaw.com/conferences.
A live audio webcast of the presentation will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary audio software. An archive of Mr. Katkin's presentation at the Rodman & Renshaw Healthcare Conference will be available on the Company's website for 30 days.
AVANIR Pharmaceuticals is focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, inflammation, and infectious diseases. AVANIR's lead product candidate, Zenvia™, is being developed for the treatment of pseudobulbar affect (PBA) and is the subject of an approvable letter from the U.S. Food and Drug Administration (FDA) for that indication. The Company has initiated a confirmatory Phase III study under a Special Protocol Assessment (SPA) agreement with the FDA utilizing a new lower quinidine dose formulation of Zenvia intended to address safety concerns raised in the Agency's approvable letter for Zenvia in the treatment of PBA. Additionally, in April 2007 AVANIR announced meeting all primary endpoints in a Phase III clinical trial with Zenvia in patients with diabetic peripheral neuropathic (DPN) pain. In May 2008 the Company released top-line results of a formal pharmacokinetic (PK) study that identified alternative lower-dose quinidine formulations of Zenvia for DPN pain intended to deliver similar efficacy and improved safety/tolerability versus the formulations previously tested for this indication. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com and further information about pseudobulbar affect can be found at www.PBAinfo.org.
To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0
AVANIR Investor Contacts
Eric Benevich or Brenna Mullen
Nov 04, 2008